Filing Flows › AIM ImmunoTech (AIM) › Q1 2026 › vs Q1 2025
AIM ImmunoTech (AIM) Q1 2026 vs Q1 2025 (year over year)
AIM ImmunoTech's revenue rose $6K (+38%) from $16K in Q1 2025 to $22K in Q1 2026.
AIM ImmunoTech, Q1 2026: revenue $22K (+38% year over year), net loss $3.0M, operating cash flow −$2.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $22K | $16K | $6K | +38% |
| Net loss | $3.0M | $3.7M | −$682K | -18% |
| Costs & expenses | $3.0M | $3.7M | −$676K | -18% |
| Operating costs | $2.2M | $3.6M | −$1.4M | -38% |
| Interest & other, net | $797K | $86K | $711K | +827% |
| Research & development | $482K | $1.1M | −$598K | -55% |
| General & admin | $1.8M | $2.5M | −$783K | -31% |
| Operating cash sources | $3.0M | $3.6M | −$622K | -17% |
| Depreciation & amortization | $43K | $58K | −$15K | -26% |
| Working capital & other | $261K | $1.2M | −$965K | -79% |
| Cash used in operations | $2.7M | $2.4M | $358K | +15% |
| Net loss absorbed | $3.0M | $3.7M | −$682K | -18% |
Questions
How much did AIM ImmunoTech's revenue grow year over year in Q1 2026?
AIM ImmunoTech's revenue rose $6K (+38%) from $16K in Q1 2025 to $22K in Q1 2026.